Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Stopped early · Phase 1

Conditions studied: Ependymoma

In brief

The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratiﬁed by primary tumor location.

Key facts

Study ID: NCT01795313
Run by: James Felker
People needed: 23
Starts: 2012-08-01
Expected to finish: 2025-12-03
Last updated by the study team: 2026-02-05

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Patients living outside of North America are not eligible.
Patients must be off concurrent treatment or medications for at least 1 week including: Interferon (e.g. Intron-A®), allergy desensitization injections, growth factors (e.g. Procrit®, Aranesp®, Neulasta®), interleukins (e.g. Proleukin®), and any investigational therapeutic medication.
Patients must not have a history of any immune system disorder or laboratory abnormality or any condition that could potentially alter immune function.
Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents. Patients must be on no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration. Topical corticosteroids are acceptable.
Patients with a known immune deficiency.
Pregnancy or breastfeeding. Female patients who are post-menarchal must have a documented negative pregnancy test.
Tetanus vaccine during therapy or within 1 week prior to enrollment.
Patients who have received prior immunotherapy.

Where it is running

Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.